How Does Dexcom Generate Its Revenue?
Dexcom is a medical device company focused on continuous glucose monitoring systems used to track glucose levels. Its business centers on selling CGM hardware and the related consumables that support ongoing use. The company operates at a large public-company scale, with an equity value around USD 28 billion. The investment debate often comes down to how durable that CGM demand and pricing power really are over time.
Are Margins and Cash Flow Holding Up?
FundamentalsFor 2025 (reported in USD), revenue reached USD 4.66 billion, with EBIT of USD 911.8 million and net income of USD 836.3 million. Year over year, revenue grew 15.6%, alongside a trailing gross margin of 63.43% and an operating margin of 21.45%.
On the balance sheet, cash was USD 917.7 million with total debt at zero. A cash-flow proxy was about USD 911.5 million, derived from after-tax EBIT plus depreciation and amortization of USD 251.8 million. Return on equity stood at 33.83% over the trailing period.
Is The Market Overpaying For Growth?
DCF / MultiplesAt USD 72.47, the stock trades above the central DCF estimate of USD 55.08, between a lower scenario of USD 32.85 and an upper case of USD 83.97. That aligns with a market valuation carrying a trailing P/E of 30.06x and an EV/EBITDA of 21.78x.
Valuation Depends On Durability
TakeawayThe price is paying for durability, not just current results. For that to hold, growth and margins need to stay resilient. Cash generation has to remain repeatable, not episodic. If growth cools or margins fade, the valuation can compress quickly. As priced, the business is assumed to keep compounding efficiently.